Abstract:Purpose: Mutation of the ATM gene may be associated with enhanced radiosensitivity and increased radiation-induced morbidity. Denaturing high performance liquid chromatography (DHPLC) is a powerful new technique proven to be sensitive and accurate in the detection of missense mutations, as well as small deletions and insertions. We screened female breast cancer patients for evidence of ATM gene alterations using DHPLC. This study attempted to determine whether breast cancer patients who develop severe radiotherapy (RT)-induced effects are more likely to possess ATM mutations than patients who display normal radiation responses. Methods and materials: Forty-six patients with early-stage breast carcinoma underwent limited surgery and adjuvant RT. DNA was isolated from blood lymphocytes, and each coding exon of the ATM gene was amplified using polymerase chain reaction. Genetic variants were identified using DHPLC by comparing test patterns with a known wild-type pattern. All variants were subjected to DNA sequencing and compared with wild-type sequences for evidence of a mutation. A retrospective review was performed, and the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer acute and late morbidity scoring schemes for skin and subcutaneous normal tissues were applied to quantify the radiation-induced effects. Results: Nine ATM mutations were identified in 6 patients (8 novel and 1 rare). The median follow-up was 3.2 years (range 1.3-10.3). A significant correlation between ATM mutation status and the development of Grade 3-4 subcutaneous late effects was found. All 3 of the patients (100%) who manifested Grade 3-4 subcutaneous late sequelae possessed ATM mutations, whereas only 3 (7%) of the 43 patients who did not develop this form of severe toxicity harbored an ATM mutation (p = 0.001). One ATM mutation carrier developed Grade 4 soft tissue necrosis after RT and required hyperbaric oxygen. All 3 patients manifesting Grade 3-4 late subcutaneous responses in fact harbored 2 ATM mutations. In contrast, none of the 3 ATM carriers who had a single mutation developed a severe subcutaneous reaction. ATM mutation status did not predict for a significant increase in early effects. Of the 23 patients with Grade 2-3 moist desquamation, 4 (17%) had an ATM mutation compared with 2 (9%) of 23 patients without desquamation (p = 0.7). Conclusion: Possession of an ATM mutation, particularly when 2 are present, may be predictive of an increase in subcutaneous late tissue effects after RT for breast cancer and may subsequently prove to be a relative contraindication to standard management. These patients may be better served with reduced doses of radiation. Equivalent local control remains to be tested, but this germline alteration may radiosensitize normal tissues, as well as the tumor itself. DHPLC is effective in the identification of these patients. A larger study is required to confirm these findings.

ATM Polymorphisms Are Associated with Radiosensitivity for Patients with Esophageal Squamous Cell Carcinoma Underwent Preoperative Radiation Therapy

Associations of ATM Polymorphisms with Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Receiving Radiation Therapy.

ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy.

Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy

Single Nucleotide Polymorphism rs1801516 in Ataxia Telangiectasia-Mutated Gene Predicts Late Fibrosis in Cancer Patients After Radiotherapy: A PRISMA-Compliant Systematic Review and Meta-Analysis.

Genetic Polymorphisms and Treatment Response in Advanced Non-Small Cell Lung Cancer.

ATM sequence variants associate with susceptibility to non-small cell lung cancer.

Association between ATM gene polymorphisms, lung cancer susceptibility and radiation-induced pneumonitis: a meta-analysis

Gene-environment Interaction for Polymorphisms in Ataxia Telangiectasia-Mutated Gene and Radiation Exposure in Carcinogenesis: Results from Two Literature-Based Meta-Analyses of 27120 Participants

P1.03-25 the Frequency and Prognosis of ATM Mutations in Chinese Non-Small-Cell Lung Cancer Patients

Genomic analysis reveals somatic mutations of ATM gene in DNA repair confer exceptional target lesion response to radiation therapy.

DNA Repair Gene ERCC1 C118T Polymorphism Predicts Sensitivity of Recurrent Esophageal Cancer to Radiochemotherapy in a Chinese Population.

Variation of ATM Protein Expression in Response to Irradiation of Lymphocytes in Lung Cancer Patients and Controls.

Single Nucleotide Polymorphism in ATM and Non-Small Cell Lung Cancer Susceptibility

Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer.

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Genetic polymorphism contributes to 131 I radiotherapy-induced toxicities in patients with differentiated thyroid cancer.

Alteration of the ATM Gene Occurs in Gastric Cancer Cell Lines and Primary Tumors Associated with Cellular Response to DNA Damage

ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects

Genetic polymorphism contributes to <sup>131</sup>I radiotherapy-induced toxicities in patients with differentiated thyroid cancer

Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer